SCHEMBL8234342

SCHEMBL8234342

C=CC1(CC(=O)OCC)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
MGAM O43451 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 3/20 0.39
TRPA1 O75762 1/20 0.39
CYP1A2 P05177 1/20 0.34
KDM4E B2RXH2 4/20 0.34
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALOX15 P16050 2/20 0.33
ELANE P08246 1/20 0.33
SOAT1 P35610 1/20 0.32
TSHR P16473 1/20 0.32
NR1I2 O75469 1/20 0.32
PGR P06401 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9796453 0.91 KDM4E (0.40) GAAMGAMSIMGAM2KMT2A
SCHEMBL6023769 0.88 TSHR (0.40) GAAMGAMSIMGAM2KMT2A
SCHEMBL19746316 0.84 GAA (0.38) GAAMGAMSIMGAM2KMT2A
SCHEMBL27300102 0.82 GAA (0.43) GAAMGAMSIMGAM2KMT2A
SCHEMBL14559644 0.82 GAA (0.36) GAAMGAMSIMGAM2KMT2A
SCHEMBL3078747 0.82 KMT2A (0.39) GAAMGAMSIMGAM2KMT2A
SCHEMBL31088807 0.76 GAA (0.40) GAAMGAMSIMGAM2KMT2A
SCHEMBL597365 0.75 KMT2A (0.51) GAAMGAMSIMGAM2KMT2A
SCHEMBL13063367 0.74 KMT2A (0.36) GAAMGAMSIMGAM2KMT2A
SCHEMBL6545242 0.74 KDM4E (0.41) GAAMGAMSIMGAM2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168821-B2 Cyclopropylacetic acid derivatives and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-01 US disclosed
US-8168821-B2 Cyclopropylacetic acid derivatives and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-01 US disclosed
US-20090286882-A1 Cyclopropylacetic Acid Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-11-19 US disclosed
US-20090286882-A1 Cyclopropylacetic Acid Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-11-19 US disclosed
CN-101346339-A Cyclopropylacetic acid derivatives and use thereof BAYER HEALTHCARE AG (DE) 2009-01-14 CN disclosed
WO-2007045367-A1 CYCLOPROPYLACETIC ACID DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286882-A1 Cyclopropylacetic Acid Derivatives and Use Thereof PCCA, PPP2CA, HMGCR GAA 117/4885MGAM 716/4885SI 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.